New combo therapy aims to keep aggressive liver cancer from coming back
NCT ID NCT05967182
Summary
This study is testing if adding the immunotherapy drug pembrolizumab to standard chemotherapy (gemcitabine and cisplatin) helps people with a type of bile duct cancer in the liver stay cancer-free longer after surgery. The treatment is given both before and after the operation. Researchers will enroll about 24 adults with high-risk but operable tumors to see if this combination improves outcomes compared to standard chemo and surgery alone.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHOLANGIOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.